Insider transactions
Hunter C. Smith, the Chief Financial Officer of Rhythm Pharmaceuticals, INC. (NASDAQ: RYTM), completed sales of 8,058 shares of common stock on February 17 and February 19, 2026, generating approximately $805,813 in proceeds. The trades were carried out across multiple transactions with executed prices ranging from $99.415 to $103.84 per share. The dispositions were made under a Rule 10b5-1 trading plan that the company adopted on February 28, 2025.
Shareholding and market context
After these sales, Smith directly holds 110,512 shares of Rhythm Pharmaceuticals. The company is assigned a market valuation of $6.88 billion and its shares are currently quoted at $103.16. Over the past 12 months the stock has risen 79 percent, though InvestingPro analysis indicates the shares may be trading above its Fair Value estimate.
Near-term corporate calendar
Rhythm is scheduled to report earnings in six days on February 26, an event that could influence near-term trading and investor expectations.
Revenue and operational developments
Rhythm reported preliminary, unaudited global net product revenues for fourth-quarter 2025 of approximately $57 million attributable to sales of IMCIVREE, an 11 percent increase from the prior quarter. For the full year 2025, the company reported net product revenues of about $194 million, representing a 50 percent increase year-over-year from 2024. The company noted that U.S. sales made up a significant portion of the annual revenue total.
Analyst coverage and price targets
Following the revenue disclosures and clinical updates, several brokerages adjusted their views on the stock. RBC Capital initiated coverage with an Outperform rating and a price target of $145.00. H.C. Wainwright raised its price target to $125.00 while maintaining a Buy rating after the company announced its revenue results. TD Cowen moved its price target to $130.00, citing the stronger-than-expected quarterly revenue of $57 million, which exceeded both consensus and the firms prior projections. Separately, H.C. Wainwright also increased a price target to $123.00 based on positive preliminary results from Rhythms Phase 2 trial of setmelanotide in patients with Prader-Willi syndrome, noting observed reductions in BMI and hyperphagia.
What this means for investors
The transactions by the CFO provide a concrete data point on insider liquidity activity while the companys recent revenue trajectory and clinical updates have prompted renewed analyst attention and higher price targets. Investors monitoring Rhythm will likely watch the upcoming earnings release and any further clinical or revenue disclosures closely.
Note - The article reports facts on insider sales, revenue figures, analyst actions, and trial results as stated by the company and referenced analysis.